Sample 16
Homo sapiens
Protocols: MD-901 multicolor-labeled (MCL) clones were cultured and exposed for three weeks to gradually increasing doses of ibrutinib (ranging from 10-fold below to 2.5-fold above the GR50). After treatment, three groups were collected: ibrutinib-sensitive (scr week 5 < week 1, n = 4), ibrutinib-resistant (scr week 5 > week 1, n = 4), and miR-28–expressing (n = 5) clones. At week 3, RFP⁺ cells were isolated by fluorescence-activated cell sorting (FACS) using a FACS Aria cell sorter for subsequent RNA extraction.  Total RNA was extracted from sorted cells using the miRNeasy Mini Kit (Qiagen) following the manufacturer's protocol. RNA libraries for RNA-seq were prepared using DNBSEQ Low Input Smart-Seq Eukaryotic mRNA library following manufacturer's protocols.
ENA first public
2026-06-26
INSDC center name
Dept. of Immunology, Ophthalmology and ENT, Universidad Complutense de Madrid; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
INSDC status
public
Submitter Id
E-MTAB-16241:Sample 16
broker name
ArrayExpress
cell line
MD-901
cell type
B cell
collection date
not collected
common name
human
disease
B-cell non-Hodgkins lymphoma
genotype
wild type genotype
geographic location (country and/or sea)
not collected
isolate
not applicable
organism part
blood
sample name
E-MTAB-16241:Sample 16
scientific_name
Homo sapiens